RT Journal Article
T1 Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
A1 Cotes Sanchís, Almudena
A1 Gallego, Javier
A1 Hernandez, Raquel
A1 Arrazubi, Virginia
A1 Custodio, Ana
A1 Cano, Juana María
A1 Aguado, Gema
A1 Macias, Ismael
A1 Lopez, Carlos
A1 López, Flora
A1 Visa, Laura
A1 Garrido, Marcelo
A1 Martínez Lago, Nieves
A1 Fernández Montes, Ana
A1 Limón, María Luisa
A1 Azkárate, Aitor
A1 Pimentel, Paola
A1 Reguera, Pablo
A1 Ramchandani, Avinash
A1 Cacho, Juan Diego
A1 Martín Carnicero, Alfonso
A1 Granja, Mónica
A1 Martín Richard, Marta
A1 Hernández Pérez, Carolina
A1 Hurtado, Alicia
A1 Serra, Olbia
A1 Buxo, Elvira
A1 Vidal Tocino, Rosario
A1 Jimenez-Fonseca, Paula
A1 Carmona-Bayonas, Alberto
AB Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's τ = 0.613), lower in those subjects who received second-line (Kendall's τ = 0.539), especially with ramucirumab+CT (Kendall's τ = 0.413). This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines.
YR 2020
FD 2020-07-31
LK http://hdl.handle.net/10668/16030
UL http://hdl.handle.net/10668/16030
LA en
DS RISalud
RD Jul 30, 2025